ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1360

Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study

Maria Antonietta D'Agostino1, Georg Schett2, Corine Gaillez3, Carlos Guerrero4, PETRA HANOVA5, Tomas Cazenave6, Maria S. Stoenoiu7, Marina Backhaus8, Gael Mouterde9, Maarten Boers10, Anne-Marie Duggan11, Punit Goyanka12 and Philip Conaghan13, 1Rheumatology, Fondazione Policlinico Universitario “Gemelli”, IRCCS, Rome, Italy, 2Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, 3Novartis Pharma AG, Basel, Switzerland, 4Dermatologico Country, Jalisco, Mexico, 5Department of Rheumatology, Institute of Rheumatology, Prague, Czech Republic, 6Instituto de Rehabilitación Psicofisica, Buenos Aires, Argentina, Buenos Aires, Argentina, 7Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 8Department of Internal Medicine, Rheumatology and Clinical Immunology, Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, Berlin, Germany, 9Rheumatology department, CHU Montpellier, Montpellier, France, 10Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 11Novartis Ireland Limited, Dublin, Ireland, Dublin, Ireland, 12Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India, 13Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Biologicals, Interleukins, Psoriatic arthritis, Synovitis, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Power Doppler ultrasound (PDUS) is a sensitive non-invasive imaging tool to visualize a wide range of articular and periarticular inflammation in psoriatic arthritis (PsA).1,2 ULTIMATE (NCT02662985) is the first large RCT that used ultrasound with Global OMERACT ultrasound synovitis score (GLOESS) as the primary endpoint, to demonstrate early benefits of secukinumab on synovitis in patients with PsA through 12 weeks.3 Here we report the responsiveness of ultrasound on synovitis and enthesitis, clinical efficacy, and safety of secukinumab up to 52 weeks.

Methods: This was a 52-week study with a 12-week double-blind placebo-controlled treatment followed by 12-week open-label treatment and 6-month open-label extension treatment in all patients. Detailed study design and eligibility criteria have been reported previously.3,4 Synovitis and ultrasound enthesitis response were measured by GLOESS and Global OMERACT enthesitis Score (Definitions 1 and 2)4 at patient level, respectively. Other assessments across key PsA manifestations of joints (ACR responses), enthesitis, (SPARCC), skin (PASI responses), dactylitis (LDI) and physical function (HAQ-DI) were also evaluated. Data are presented as observed.

Results: A total of 166 patients were enrolled, of which 90% (75/83) of secukinumab and 83% (69/83) of placebo-secukinumab participants completed 52 weeks. A continued improvement in GLOESS was observed in both secukinumab and placebo-secukinumab group after switch to active therapy at Week 12 through Week 52 (Figure 1). A similar trend of improvement in Global OMERACT enthesitis score (Definition 1 and 2) was observed up to 52 weeks in both groups (Figure 2). Sustained clinical response rates were observed across multiple facets of disease and physical function up to 52 weeks in both secukinumab and placebo-secukinumab groups (Table). There were no new or unexpected safety findings.

Conclusion: ULTIMATE demonstrated the responsiveness of ultrasound on both synovitis and enthesitis outcomes in PsA supporting its use in clinical trials, and confirmed the rapid and continued benefits of secukinumab through 52 weeks. Sustained efficacy was also observed across key clinical PsA manifestations with a safety profile consistent with previous reports.

References:
1. D’Agostino MA and Coates LC. J Rheumatol 2019;46:337–9
2. Uson J, et al. Rheumatol Clin 2018;14:27–35
3. D’Agostino MA, et al. Arthritis Rheumatol 2020;72 (suppl 10)
4. Boers M et al. Ann Rheum Dis 2021;80:314

Figure 1: Mean change from baseline in GLOESS by treatment up to Week 52

Figure 2: Mean change from baseline Global OMERACT enthesitis score up to Week 52

Table: Clinical efficacy outcomes at Week 52 (Extension period)


Disclosures: M. D'Agostino, Sanofi, 2, 6, Novartis, 2, 6, BMS, 2, 6, Janssen, 2, 6, Celgene, 2, 6, Roche, 2, 6, AbbVie, 2, 6, UCB, 2, 6, Eli Lilly, 2, 6; G. Schett, Janssen, 6, Novartis, 6, AbbVie, 6, Bristol Myers Squibb, 6, Celgene, 6, Eli Lilly, 6, UCB, 6, Roche, 6; C. Gaillez, Novartis Pharma AG, 3, 11, BMS, 11; C. Guerrero, None; P. HANOVA, None; T. Cazenave, None; M. Stoenoiu, AbbVie, 2, 5, 6, UCB, 2, 5, 6, Pfizer, 2, 5, 6, MSD, 2, 5, 6, Roche, 2, 5, 6; M. Backhaus, BMS, 2, 5, 6, AbbVie, 2, 5, 6, Gilead, 2, 5, 6, Jonsson, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, UCB, 2, 5, 6; G. Mouterde, AbbVie, 2, 5, 6, BMS, 2, 5, 6, Celgene, 2, 5, 6, Lilly, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6; M. Boers, BMS, 2, Novartis, 2, GSK, 2, Pfizer, 2; A. Duggan, Novartis, 3; P. Goyanka, Novartis, 3; P. Conaghan, AbbVie, 2, 6, BMS, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, AstraZeneca, 2, 6.

To cite this abstract in AMA style:

D'Agostino M, Schett G, Gaillez C, Guerrero C, HANOVA P, Cazenave T, Stoenoiu M, Backhaus M, Mouterde G, Boers M, Duggan A, Goyanka P, Conaghan P. Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/ultrasound-demonstrates-continued-improvement-in-psoriatic-arthritis-synovitis-and-enthesitis-with-secukinumab-52-week-results-from-a-phase-iii-study/. Accessed June 2, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultrasound-demonstrates-continued-improvement-in-psoriatic-arthritis-synovitis-and-enthesitis-with-secukinumab-52-week-results-from-a-phase-iii-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences